keyword
MENU ▼
Read by QxMD icon Read
search

Rheumatology;biologics

keyword
https://www.readbyqxmd.com/read/29317823/european-perspective-on-the-management-of-rheumatoid-arthritis-clinical-utility-of-tofacitinib
#1
REVIEW
Paweł Kawalec, Katarzyna Śladowska, Iwona Malinowska-Lipień, Tomasz Brzostek, Maria Kózka
Xeljanz® (tofacitinib) is an oral small-molecule inhibitor that reversibly inhibits Janus-activated kinase (JAK)-dependent cytokine signaling, thus reducing inflammation. As a result of these mechanisms, effects on the immune system such as a moderate decrease in the total lymphocyte count, a dose-dependent decrease in natural killer (NK) cell count, and an increase in B-cell count have been observed. Therefore, tofacitinib provides an innovative approach to modulating the immune and inflammatory responses in patients with rheumatoid arthritis (RA), which is especially important in individuals who do not respond to tumor necrosis factor inhibitors or show a loss of response over time...
2018: Therapeutics and Clinical Risk Management
https://www.readbyqxmd.com/read/29298172/psoriatic-arthritis-in-nigeria-case-series-and-literature-review
#2
Akpabio Akanimo Akpabio, Babatunde Hakeem Olaosebikan, Olufemi Oladipo Adelowo
BACKGROUND: Psoriatic arthritis (PsA) is an extracutaneous manifestation of psoriasis occurring in 6% to 42% of patients. Both conditions are common among whites but rarely reported among black Africans.Few African studies, however, have reported PsA frequencies of 0% to 4.6%, with a previous case report of 2 patients from a Nigerian rheumatology clinic. METHODS: Case records of PsA patients from the Lagos State University Teaching Hospital Rheumatology Clinic seen over a 5-year period from January 2012 to December 2016 were retrieved and documented...
January 3, 2018: Journal of Clinical Rheumatology: Practical Reports on Rheumatic & Musculoskeletal Diseases
https://www.readbyqxmd.com/read/29290076/risk-of-serious-infections-in-biological-treatment-of-patients-with-ankylosing-spondylitis-and-non-radiographic-axial-spondyloarthritis-a-meta-analysis
#3
Sen Wang, Qian He, Zongwen Shuai
The objective of the study is to quantitatively assess the risk of serious infections in patients with axial spondyloarthritis (AS) and non-radiographic axial spondyloarthritis (nr-axSpA) treated by biologics enrolled in randomized controlled trials (RCTs). A systematic literature searches of MEDLINE (via PubMed), EMBASE, the Cochrane Library and abstracts archives of the annual scientific meetings of both the American College of Rheumatology (ACR) and the European League Against Rheumatism (EULAR) was conducted through October 2015...
December 30, 2017: Clinical Rheumatology
https://www.readbyqxmd.com/read/29288517/proposal-for-the-development-of-biologics-in-pediatric-rheumatology-field
#4
REVIEW
Masaaki Mori, Masao Nakagawa, Nao Tsuchida, Kou Kawada, Junko Sato, Michiyo Sakiyama, Shinya Hirano, Katsuaki Sato, Hidefumi Nakamura
In order to aim at the development, approval and early introduction into clinical practice of biologics in pediatric field, we investigated the present situation of the development to approval of biologics as anti-rheumatic agents for children in Japan, visualize the present problems and give a proposal for the future. As results of analysis in various directions, it is apparent that the duration of a review period required for the preparation of clinical trials and the approval in PMDA clearly reduced compared with the past...
December 29, 2017: Pediatrics International: Official Journal of the Japan Pediatric Society
https://www.readbyqxmd.com/read/29285605/comparative-effectiveness-of-abatacept-apremilast-secukinumab-and-ustekinumab-treatment-of-psoriatic-arthritis-a-systematic-review-and-network-meta-analysis
#5
REVIEW
P Kawalec, P Holko, P Moćko, A Pilc
To assess the comparative effectiveness and safety of novel biologic therapies in psoriatic arthritis (PsA) and to establish the position of the non-anti-tumor necrosis factor α (TNF-α) biologic drugs in the treatment regimen of the disease. A systematic review and network meta-analysis (NMA) was conducted according to the preferred reporting items for systematic reviews and meta-analyses (PRISMA) requirements. Two investigators identified the studies, abstracted data, and assessed the risk of bias independently...
December 28, 2017: Rheumatology International
https://www.readbyqxmd.com/read/29275332/dual-il-17a-and-il-17f-neutralisation-by-bimekizumab-in-psoriatic-arthritis-evidence-from-preclinical-experiments-and-a-randomised-placebo-controlled-clinical-trial-that-il-17f-contributes-to-human-chronic-tissue-inflammation
#6
Sophie Glatt, Dominique Baeten, Terry Baker, Meryn Griffiths, Lucian Ionescu, Alastair D G Lawson, Ash Maroof, Ruth Oliver, Serghei Popa, Foteini Strimenopoulou, Pavan Vajjah, Mark I L Watling, Nataliya Yeremenko, Pierre Miossec, Stevan Shaw
OBJECTIVE: Interleukin (IL)-17A has emerged as pivotal in driving tissue pathology in immune-mediated inflammatory diseases. The role of IL-17F, sharing 50% sequence homology and overlapping biological function, remains less clear. We hypothesised that IL-17F, together with IL-17A, contributes to chronic tissue inflammation, and that dual neutralisation may lead to more profound suppression of inflammation than inhibition of IL-17A alone. METHODS: Preclinical experiments assessed the role of IL-17A and IL-17F in tissue inflammation using disease-relevant human cells...
December 23, 2017: Annals of the Rheumatic Diseases
https://www.readbyqxmd.com/read/29261674/mitochondrial-haplogroups-in-patients-with-rheumatoid-arthritis-no-association-with-disease-and-disease-manifestations
#7
Pernille Hurup Duhn, Jacob Sode, Christian Munch Hagen, Michael Christiansen, Henning Locht
OBJECTIVE: To describe the distribution of specific mitochondrial DNA (mtDNA) haplogroups (hgs) in a cohort of patients with rheumatoid arthritis (RA). METHODS: Two-hundred nineteen consecutive patients with RA had mtDNA isolated from their blood, sequenced and haplotyped. Patients were diagnosed according to the American College of Rheumatology (ACR)/European league against Rheumatism (EULAR) criteria. Demographic and clinical data were retrieved from the Danish nationwide database (DANBIO)...
2017: PloS One
https://www.readbyqxmd.com/read/29251024/outcome-of-transition-phase-patients-with-juvenile-idiopathic-arthritis
#8
Heikki Relas, Riitta Luosujärvi, Silja Kosola
OBJECTIVES: Across diagnosis groups, successful transition of adolescent and young adults from children's hospitals to adult care is often associated with decreased treatment adherence and treatment results. The aim of this study was to characterize disease activity and anti-rheumatic medications following transfer of care of juvenile idiopathic arthritis (JIA) patients to the adult clinic. METHOD: All consecutive JIA patients aged 16 to 20 years who visited the specific transition clinic in the rheumatology outpatient clinic of Helsinki University Hospital between November 2012 and May 2013 and between April 2015 and April 2016 were evaluated...
December 18, 2017: Modern Rheumatology
https://www.readbyqxmd.com/read/29247389/degree-of-prescriber-s-knowledge-about-variability-in-biological-drugs-innovators-in-manufacturing-process
#9
Lucía Jiménez-Pichardo, Rocío Gázquez-Pérez, Jesús Francisco Sierra-Sánchez
PURPOSE: The purpose of the study is to analyse the degree of prescribers' knowledge about the regulation and variability in manufacturing processes (MP) in bio-drugs "innovators" (BI). METHODS: For each selected drugs, the date of authorization by the European Medicines Agency, time elapsed until the first change, total number of changes and annual rate of change (ARC) were recorded. A survey was designed with 4 parts: (a) identifying the BI prescribed; (b) knowledge of the number and ARC of each BI during its MP; (c) knowledge of comparability requirement of BI before or after the MP; (d) evaluating the utility of the information in the survey...
December 15, 2017: European Journal of Clinical Pharmacology
https://www.readbyqxmd.com/read/29246248/factors-associated-with-the-6-minute-walk-distance-in-patients-with-systemic-sclerosis
#10
Sébastien Sanges, Jonathan Giovannelli, Vincent Sobanski, Sandrine Morell-Dubois, Hélène Maillard, Marc Lambert, Céline Podevin, Nicolas Lamblin, Pascal De Groote, Jean-François Bervar, Thierry Perez, Régis Matran, Martine Rémy-Jardin, Pierre-Yves Hatron, Éric Hachulla, David Launay
BACKGROUND: There is an ongoing debate regarding the relevance of the 6-minute walking distance (6MWD) in systemic sclerosis (SSc) assessment, widely used as a usual test in these patients as well as an outcome measure in clinical trials. In this work, we aimed to assess the associations between the 6MWD and various disease parameters in patients with SSc. METHODS: Consecutive patients followed in our SSc National Reference Centre were included in this cross-sectional study if they fulfilled the 2013 American College of Rheumatology/European League Against Rheumatism criteria for SSc...
December 15, 2017: Arthritis Research & Therapy
https://www.readbyqxmd.com/read/29226452/clinical-characteristics-of-japanese-patients-with-psoriatic-arthritis-comparison-with-east-asian-countries
#11
REVIEW
Toshiyuki Yamamoto, Akira Kawada
To determine the characteristics and current status of Japanese patients with psoriatic arthritis, the Japanese Society for Psoriasis Research have started to conduct retrospective questionnaire surveys. The results collected from over a thousand patients with psoriatic arthritis have revealed several characteristics. The newly visited psoriatic arthritis patients accounted for approximately 10% of all new psoriatic patients who visited the dermatology department in many referral centers. The prevalence was nearly 15% of psoriatic patients, which was similar to a recent rheumatology and dermatology study in Japan with a large cohort...
December 10, 2017: Journal of Dermatology
https://www.readbyqxmd.com/read/29196381/sharing-ongoing-care-with-primary-care-physicians-opens-up-opportunity-for-timelier-and-earlier-care-by-rheumatologists-for-patients-with-new-inflammatory-polyarthritis
#12
Patrick Nguyen, Anne-Sophie Julien, Louis Bessette, Paul R Fortin, Laëtitia Michou
OBJECTIVE: In our region in Quebec, Canada, access to rheumatologists is very limited. Sharing followup of stable patients with their primary care physicians (PCP) could increase access to rheumatologists. In our study, we assessed the feasibility and potential benefits of sharing followup of inflammatory arthritis (IA) patients with their PCP. METHODS: We reviewed the clinical records of 300 patients with peripheral arthritis who presented at our rheumatology outpatient clinic between July and October 2015...
December 1, 2017: Journal of Rheumatology
https://www.readbyqxmd.com/read/29195024/tuberculosis-risk-in-ankylosing-spondylitis-other-spondyloarthritis-and-psoriatic-arthritis-in-sweden-a-population-based-cohort-study
#13
Mirjam K de Vries, Elizabeth V Arkema, Jerker Jonsson, Judith Bruchfeld, Lennart Th Jacobsson, Johan Askling
OBJECTIVES: Rheumatoid arthritis (RA) is a risk factor for tuberculosis (TB), particularly following treatment with biologicals. Since these therapies are increasingly used in ankylosing spondylitis (AS), other types of spondyloarthritis (SpA) and psoriatic arthritis (PsA), we investigated the corresponding TB risks in these patients. METHODS: We identified individuals with AS/SpA/PsA, and non-AS/SpA/PsA comparators by linking Swedish national Patient, Population, TB and Rheumatology registers, and followed them for TB occurrence...
December 1, 2017: Arthritis Care & Research
https://www.readbyqxmd.com/read/29193136/clinical-indications-for-intravenous-immunoglobulin-utilization-in-a-tertiary-medical-center-a-9-year-retrospective-study
#14
Asaf Shemer, Shaye Kivity, Yehuda Shoenfeld
BACKGROUND: Intravenous immunoglobulins (IVIG) are a biologic product originally developed to treat immunocompromised patients. In the past decades, there has been increased utilization of IVIG in autoimmune conditions. The objectives were to evaluate the clinical use of IVIG in the largest tertiary medical center in Israel and to determine top uses, estimate off-label usage, and assess consumption of this blood product. STUDY DESIGN AND METHODS: We conducted an observational, retrospective study involving all patients who received IVIG from 2007 through 2015...
November 27, 2017: Transfusion
https://www.readbyqxmd.com/read/29189134/the-economic-impact-of-biosimilars-on-chronic-immune-mediated-inflammatory-diseases
#15
Marta Pentek, Zsombor Zrubka, Laszlo Gulacsi
BACKGROUND: Biological drugs represent highly effective but costly treatments for chronic immune-mediated inflammatory diseases posing substantial burden on health care budgets. Introduction of biosimilars since 2013 has brought forward the potential of market competition, and as a societal benefit, the hope of increased access at a lower cost. OBJECTIVE: We aim to provide a descriptive review on economic aspects and market changes related to the introduction of biosimilar drugs...
November 29, 2017: Current Pharmaceutical Design
https://www.readbyqxmd.com/read/29185959/recommendations-for-the-use-of-biologics-and-other-novel-drugs-in-the-treatment-of-psoriatic-arthritis-2017-update-from-the-italian-society-of-rheumatology
#16
Antonio Marchesoni, Ignazio Olivieri, Carlo Salvarani, Nicolò Pipitone, Salvatore D'Angelo, Alessandro Mathieu, Alberto Cauli, Leonardo Punzi, Roberta Ramonda, Raffaele Scarpa, Mara Maccarone, Ennio Lubrano
OBJECTIVES: To update the 2011 Italian Society of Rheumatology (SIR) recommendations for the use of biologics and other novel agents in the treatment of psoriatic arthritis (PsA). METHODS: To create this new set of recommendations, the SIR "Spondyloartritis and Psoriatic Arthritis study group - A. Spadaro" went through the following steps: literature search, identification of the items of interests for each of the four previously identified clinical domains of PsA and the different treatment phases, achievement of the consensus on all topics, and generation of the recommendations...
November 2017: Clinical and Experimental Rheumatology
https://www.readbyqxmd.com/read/29185281/ankylosing-spondylitis-and-neck-pain-mri-evidence-for-joint-and-entheses-inflammation-at-the-craniocervial-junction
#17
Cheri Korb, Abid Awisat, Doron Rimar, Itzhak Rosner, Arsen Schpigelman, Daniela Militianu, Gleb Slobodin
BACKGROUND: Magnetic resonance imaging (MRI), which has recently become the leading imaging modality in the study of ankylosing spondylitis (AS), has not been evaluated in the assessment of disease-specific changes at the craniocervical junction (CCJ) in patients with AS. OBJECTIVES: To describe the spectrum of active inflammatory lesions at the CCJ using MRI in a cohort of patients with AS and neck pain. METHODS: The study included 18 patients with AS presenting with neck pain and a control group of 9 fibromyalgia patients matched for age and levels of neck pain...
November 2017: Israel Medical Association Journal: IMAJ
https://www.readbyqxmd.com/read/29176449/can-appropriate-systemic-treatment-help-protect-the-cornea-in-patients-with-rheumatoid-arthritis-a-multidisciplinary-approach-to-autoimmune-ocular-involvement
#18
Manuel J Amador-Patarroyo, Emilio Jalil-Florencia, Oscar Otero-Marquez, Nicolás Molano-Gonzalez, Ruben D Mantilla, Adriana Rojas-Villarraga, Juan-Manuel Anaya, Carmen Barraquer-Coll
PURPOSE: To correlate rheumatologic with ophthalmic and laboratory findings in patients with rheumatoid arthritis (RA) to identify what effect these have on development of ocular disease. METHODS: This is a cross-sectional study of 172 eyes of 86 patients with RA. Patients were examined by a group of rheumatologists. Sociodemographic, clinical, and laboratory data were collected. All patients underwent complete ophthalmologic examination including corneal topography and endothelial cell count...
November 22, 2017: Cornea
https://www.readbyqxmd.com/read/29166924/experience-with-etanercept-tocilizumab-and-interleukin-1-inhibitors-in-systemic-onset-juvenile-idiopathic-arthritis-patients-from-the-biker-registry
#19
Gerd Horneff, Anna Carina Schulz, Jens Klotsche, Anton Hospach, Kirsten Minden, Ivan Foeldvari, Ralf Trauzeddel, Gerd Ganser, Frank Weller-Heinemann, Johannes Perter Haas
BACKGROUND: Treatment of systemic onset juvenile idiopathic arthritis JIA (sJIA), although dramatically improved, remains a challenge. Experience from clinical practice will be presented using data from the German Biologics register (BiKeR) for evaluation of efficacy and safety of treatment with etanercept (ETA), tocilizumab (TOC) and the interleukin-1 inhibitors anakinra and canakinumab (IL-1i) in sJIA. METHODS: Patients with sJIA documented in the BIKeR register, who were exposed to ETA, TOC or IL-1i were identified...
November 22, 2017: Arthritis Research & Therapy
https://www.readbyqxmd.com/read/29164002/biological-therapy-in-arthritis-patients-with-hepatitis-b-or-c-infection-a-multicenter-retrospective-case-series
#20
Sultana Abdulaziz, Hussein Halabi, Mohammed A Omair, Suzan Attar, Abdullah Alghamdi, Mohammed Shabrawishi, Abdulwahab Neyazi, Haneen Alnazzawi, Nuha Meraiani, Hani Almoallim
Objective: Reactivation of viral hepatitis B (HBV) and C (HCV) has been reported in various case reports of patients with arthritis on biological therapy. The objective of this study was to describe the clinical characteristics and outcomes of arthritis patients with HBV or HCV treated with biological therapy. Material and Methods: This is a retrospective case series including all patients above 13 years of age with arthritis patients from four centers in Saudi Arabia with concurrent chronic viral hepatitis infection (HBV or HCV) who received biological agents in the rheumatology clinics during their course of their disease from duration of the disease onset until last outpatient visit up to November 2015...
September 2017: European Journal of Rheumatology
keyword
keyword
47772
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"